These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 32507446)

  • 1. A pilot study of the effect of curcumin on epigenetic changes and DNA damage among patients with non-alcoholic fatty liver disease: A randomized, double-blind, placebo-controlled, clinical trial.
    Hariri M; Gholami A; Mirhafez SR; Bidkhori M; Sahebkar A
    Complement Ther Med; 2020 Jun; 51():102447. PubMed ID: 32507446
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of phytosomal curcumin among patients with non-alcoholic fatty liver disease.
    Mirhafez SR; Rezai A; Dehabeh M; Nobakht M Gh BF; Bidkhori M; Sahebkar A; Hariri M
    Int J Vitam Nutr Res; 2021 Jun; 91(3-4):278-286. PubMed ID: 31818232
    [No Abstract]   [Full Text] [Related]  

  • 3. Effect of Phytosomal Curcumin on Circulating Levels of Adiponectin and Leptin in Patients with Non-Alcoholic Fatty Liver Disease: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial.
    Mirhafez SR; Farimani AR; Dehhabe M; Bidkhori M; Hariri M; Ghouchani BF; Abdollahi F
    J Gastrointestin Liver Dis; 2019 Jun; 28():183-189. PubMed ID: 31204416
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and Safety of Phytosomal Curcumin in Non-Alcoholic Fatty Liver Disease: A Randomized Controlled Trial.
    Panahi Y; Kianpour P; Mohtashami R; Jafari R; Simental-Mendía LE; Sahebkar A
    Drug Res (Stuttg); 2017 Apr; 67(4):244-251. PubMed ID: 28158893
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effect of curcumin with piperine supplementation on pro-oxidant and antioxidant balance in patients with non-alcoholic fatty liver disease: a randomized, double-blind, placebo-controlled trial.
    Mirhafez SR; Farimani AR; Gholami A; Hooshmand E; Tavallaie S; Nobakht M Gh BF
    Drug Metab Pers Ther; 2019 May; 34(2):. PubMed ID: 31145689
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Effect of Curcumin Phytosome on the Treatment of Patients with Non-alcoholic Fatty Liver Disease: A Double-Blind, Randomized, Placebo-Controlled Trial.
    Mirhafez SR; Azimi-Nezhad M; Dehabeh M; Hariri M; Naderan RD; Movahedi A; Abdalla M; Sathyapalan T; Sahebkar A
    Adv Exp Med Biol; 2021; 1308():25-35. PubMed ID: 33861434
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of Non-alcoholic Fatty Liver Disease with Curcumin: A Randomized Placebo-controlled Trial.
    Rahmani S; Asgary S; Askari G; Keshvari M; Hatamipour M; Feizi A; Sahebkar A
    Phytother Res; 2016 Sep; 30(9):1540-8. PubMed ID: 27270872
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A pilot study of the effect of phospholipid curcumin on serum metabolomic profile in patients with non-alcoholic fatty liver disease: a randomized, double-blind, placebo-controlled trial.
    Chashmniam S; Mirhafez SR; Dehabeh M; Hariri M; Azimi Nezhad M; Nobakht M Gh BF
    Eur J Clin Nutr; 2019 Sep; 73(9):1224-1235. PubMed ID: 30647436
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of curcumin plus piperine co-supplementation in moderate-to-high hepatic steatosis: A double-blind, randomized, placebo-controlled clinical trial.
    Sharifi S; Bagherniya M; Khoram Z; Ebrahimi Varzaneh A; Atkin SL; Jamialahmadi T; Sahebkar A; Askari G
    Phytother Res; 2023 Jun; 37(6):2217-2229. PubMed ID: 36799355
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Curcumin and Piperine Combination for the Treatment of Patients with Non-alcoholic Fatty Liver Disease: A Double-Blind Randomized Placebo-Controlled Trial.
    Mirhafez SR; Dehabeh M; Hariri M; Farimani AR; Movahedi A; Naderan RD; Jamialahmadi T; Simental-Mendía LE; Sahebkar A
    Adv Exp Med Biol; 2021; 1328():11-19. PubMed ID: 34981468
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of phytosomal curcumin on anthropometric parameters, insulin resistance, cortisolemia and non-alcoholic fatty liver disease indices: a double-blind, placebo-controlled clinical trial.
    Cicero AFG; Sahebkar A; Fogacci F; Bove M; Giovannini M; Borghi C
    Eur J Nutr; 2020 Mar; 59(2):477-483. PubMed ID: 30796508
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effect of curcumin on anthropometric indices, blood pressure, lipid profiles, fasting blood glucose, liver enzymes, fibrosis, and steatosis in non-alcoholic fatty livers.
    Safari Z; Bagherniya M; Khoram Z; Ebrahimi Varzaneh A; Heidari Z; Sahebkar A; Askari G
    Front Nutr; 2023; 10():1163950. PubMed ID: 37275651
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pinitol consumption improves liver health status by reducing oxidative stress and fatty acid accumulation in subjects with non-alcoholic fatty liver disease: A randomized, double-blind, placebo-controlled trial.
    Lee E; Lim Y; Kwon SW; Kwon O
    J Nutr Biochem; 2019 Jun; 68():33-41. PubMed ID: 31030165
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of curcuminoids on inflammatory status in patients with non-alcoholic fatty liver disease: A randomized controlled trial.
    Saberi-Karimian M; Keshvari M; Ghayour-Mobarhan M; Salehizadeh L; Rahmani S; Behnam B; Jamialahmadi T; Asgary S; Sahebkar A
    Complement Ther Med; 2020 Mar; 49():102322. PubMed ID: 32147075
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effect of alpha-lipoic acid on inflammatory markers and body composition in obese patients with non-alcoholic fatty liver disease: A randomized, double-blind, placebo-controlled trial.
    Hosseinpour-Arjmand S; Amirkhizi F; Ebrahimi-Mameghani M
    J Clin Pharm Ther; 2019 Apr; 44(2):258-267. PubMed ID: 30585337
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Unique features associated with hepatic oxidative DNA damage and DNA methylation in non-alcoholic fatty liver disease.
    Nishida N; Yada N; Hagiwara S; Sakurai T; Kitano M; Kudo M
    J Gastroenterol Hepatol; 2016 Sep; 31(9):1646-53. PubMed ID: 26875698
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effects of curcumin supplementation on liver enzymes, lipid profile, glucose homeostasis, and hepatic steatosis and fibrosis in patients with non-alcoholic fatty liver disease.
    Saadati S; Hatami B; Yari Z; Shahrbaf MA; Eghtesad S; Mansour A; Poustchi H; Hedayati M; Aghajanpoor-Pasha M; Sadeghi A; Hekmatdoost A
    Eur J Clin Nutr; 2019 Mar; 73(3):441-449. PubMed ID: 30610213
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effects of curcumin supplementation on liver function, metabolic profile and body composition in patients with non-alcoholic fatty liver disease: A systematic review and meta-analysis of randomized controlled trials.
    Jalali M; Mahmoodi M; Mosallanezhad Z; Jalali R; Imanieh MH; Moosavian SP
    Complement Ther Med; 2020 Jan; 48():102283. PubMed ID: 31987259
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Is There a Role for Curcumin Supplementation in the Treatment of Non-Alcoholic Fatty Liver Disease? The Data Suggest Yes.
    Zabihi NA; Pirro M; Johnston TP; Sahebkar A
    Curr Pharm Des; 2017; 23(7):969-982. PubMed ID: 27748192
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fatty liver mediated by peroxisome proliferator-activated receptor-α DNA methylation can be reversed by a methylation inhibitor and curcumin.
    Li YY; Tang D; Du YL; Cao CY; Nie YQ; Cao J; Zhou YJ
    J Dig Dis; 2018 Jul; 19(7):421-430. PubMed ID: 29802754
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.